JW and JZ Modifiers: Mapping Discarded Drug Amounts to Documentation

One vial, two claim lines: the discard decision in one pass

When a healthcare provider draws a 95-unit dose of a separately payable Medicare Part B drug from a 100-unit single-dose vial and discards the remaining 5 units, the Claims Processing Manual example uses an exact two-line claim: line 1 reports the Healthcare Common Procedure Coding System (HCPCS) code with the 95 administered units and no modifier, while line 2 reports the identical HCPCS code with the 5 discarded units and modifier JW. Conversely, when the entire contents of a single-dose container are administered or when no billable drug is discarded, the provider submits a single claim line reporting the administered units with modifier JZ. CMS uses the pair to separate administered units from discarded units. For dates of service on or after July 1, 2023, claims that omit the appropriate modifier may be selected for audit, and for dates of service on or after October 1, 2023, they may be returned as unprocessable until resubmitted. Payment for the discarded amount still runs only up to the labeled amount and remains subject to review.

Navigating this decision requires clearing two gates before selecting a modifier. First, the drug must be packaged in an FDA-labeled single-dose container or single-use package. Discarded volume from a multi-dose container is not payable under Medicare Part B, and JW is not the correct modifier for that discard. Second, the billing-unit threshold must be evaluated. JW is not permitted when one HCPCS billing unit already equals or exceeds the dose administered plus the amount discarded. If a clinician administers 7 mg from a single-dose vial billed in 10 mg increments, the 3 mg remainder cannot be billed on a JW line. CMS does not accept fractional billing units, so the 7 mg dose is billed as one whole unit. That one unit already accounts for the 10 mg vial. A second JW line billed as another whole unit would claim 20 mg. In that case the correct submission is one line of one unit with modifier JZ.

Every JW or JZ claim still needs a medical record that can stand on its own in a Medicare Administrative Contractor (MAC) review or a Comprehensive Error Rate Testing (CERT) review. The claim form does not replace that record. MAC instructions identify three fields: the dose administered, the exact amount discarded, and the amount the container is labeled to contain. CMS does not prescribe the form, the author, or the storage location. Since October 1, 2023, a Part B claim for a single-dose container drug that does not use JW or JZ as appropriate may be returned as unprocessable until the provider resubmits it. Separately, Section 90004 of the Infrastructure Investment and Jobs Act added Section 1847A(h) of the Social Security Act, and CMS uses JW-reported discarded units to calculate manufacturer refunds for refundable single-dose drugs. The chart is what makes the billed units defensible; it is not itself the refund assessment.

flowchart TD
    A["Drug Drawn from Container"] --> B{"Is container FDA-labeled\nsingle-dose or single-use?"}
    B -- "No (Multi-Dose Container)" --> C["Do NOT use JW or JZ\nBill administered units only"]
    B -- "Yes (Single-Dose Container)" --> D{"Was any unused drug\ndiscarded?"}
    D -- "No Wastage" --> E["Bill 1 Claim Line:\nAdministered units + JZ modifier"]
    D -- "Drug Discarded" --> F{"Does 1 HCPCS billing unit\ncover dose plus discard?"}
    F -- "Yes (e.g., 7 mg of 10 mg unit)" --> G["Bill 1 Claim Line:\n1 unit + JZ modifier (JW prohibited)"]
    F -- "No (Discard >= 1 billing unit)" --> H["Bill 2 Claim Lines:\nLine 1: Administered units (No Mod)\nLine 2: Discarded units + JW modifier"]
    E --> I["Reconcile Medical Record:\n1. Labeled container content\n2. Actual dose administered\n3. Exact quantity discarded"]
    G --> I
    H --> I

Which containers count: single-dose, single-use, ampules, and the 2 mL rule

The threshold determination for JW and JZ modifier applicability rests strictly on container classification as defined in FDA-approved product labeling. According to FDA guidance and United States Pharmacopeia (USP) General Chapter <659>, a single-dose container is a container of a sterile medication for parenteral administration that is designed for use with a single patient as a single injection or infusion. Common single-dose packaging includes unpreserved glass or plastic vials, ampules, and prefilled syringes. Because single-dose containers do not contain antimicrobial preservatives, any unused medication exposed to ambient air or needle penetration degrades rapidly and poses severe contamination risks if stored. Medicare Part B payment policy accommodates this clinical reality by reimbursing both the administered dose and the unavoidable discarded residual, up to the labeled capacity of the vial.

Multi-dose containers are formulated for more than one entry and, when labeled as multi-dose, are outside the JW and JZ policy. Under CMS Claims Processing Manual Chapter 17, Section 40, Medicare does not pay for discarded amounts from a multi-dose container. If a practice discards remaining volume because of expiration, mishandling, or a cancelled visit, that cost stays with the practice. JW is not appropriate on a multi-dose container claim.

To assist billing departments in identifying applicable single-dose drugs, CMS publishes the JW Modifier and JZ Modifier Policy HCPCS Codes list, updated approximately semi-annually (with the latest comprehensive baseline released on June 20, 2025). This reference catalog identifies dozens of high-cost specialty injectable HCPCS codes that exclusively represent single-dose containers—including major biologics such as adalimumab (J0135), lecanemab (J0174), aflibercept (J0178), and high-dose aflibercept (J0177). However, CMS explicitly cautions that this list is non-exhaustive. More importantly, HCPCS codes that map to both single-dose and multi-dose packaging configurations across different National Drug Codes (NDCs) are intentionally excluded from the list. Providers cannot cite the absence of a HCPCS code from the CMS reference list as justification for omitting JW or JZ; compliance is governed by the physical container administered to the beneficiary.

A separate test applies only to the manufacturer refund program, not to whether a claim needs JW or JZ. At 42 CFR § 414.902, the definition of a refundable single-dose container or single-use package drug adds two labeling presumptions for products that lack container-type language:

• Ampules without container-type labeling: An ampule whose labeling has neither a discard statement nor language identifying the container as single-dose, single-use, multiple-dose, or single-patient-use is treated as a single-dose container for the refundable-drug definition. That presumption does not, by itself, rewrite the claims-side test, which still follows FDA labeling and the manual.

• Small containers of 2.0 mL or less: A container with a total labeled volume of 2 mL or less, and without language identifying it as single-dose, single-use, multiple-dose, or single-patient-use, is also treated as single-dose for the refundable-drug definition under 42 CFR § 414.902. Use this rule to scope refund exposure. Do not use it as a shortcut for deciding whether JW or JZ belongs on the claim.

Exclusions from the refund program are not exemptions from claim-level modifier reporting. Under 42 CFR § 414.902, a refundable drug is a single-source drug or biological, or a biosimilar, and the definition excludes therapeutic and diagnostic radiopharmaceuticals and imaging agents; drugs whose labeling requires filtration during preparation and discard of the unused portion after filtration; and a drug approved or licensed on or after November 15, 2021, until the last day of the sixth full quarter it has been marketed. Manufacturers owe no refund on those excluded amounts. Providers billing a single-dose container drug under Part B, including a multiple-source drug that is outside the refundable-drug definition, still report JW or JZ when the claims policy applies.

The record: what CMS requires, what it leaves open, what payers add

A widespread misconception in healthcare revenue cycle management is that CMS prescribes a rigid, universal form for documenting discarded drugs. In reality, CMS Claims Processing Manual Chapter 17 Section 40 and official CMS FAQs (updated January 10, 2025, Q19–Q20) establish an outcome-based documentation framework. CMS mandates that the medical record, purchasing logs, and inventory data must accurately corroborate the billed service, but CMS intentionally leaves the format, physical location, and authoring workflow to provider discretion. Crucially, CMS explicitly permits electronic health record (EHR) software to calculate discarded amounts automatically, provided the algorithm’s inputs—labeled vial content and administered dose—are accurate and fully audited.

Medicare Administrative Contractors have distilled CMS’s overarching standards into three non-negotiable medical record fields that must be present in every single-dose drug encounter:

1. Actual dose administered: The precise numerical dose given to the patient, expressed in metric units (mg, mcg, mL) or biological units matching clinical orders.

2. Exact amount discarded: The residual amount of drug remaining in the vial that was physically discarded under aseptic standards, calculated as the labeled container volume minus the administered dose.

3. Total labeled container content: The total quantity or volume the single-dose vial was labeled to contain by the manufacturer, verifying that the sum of administered and discarded amounts reconciles perfectly.

CMS does not require a separate destruction-protocol statement. The modifier descriptors do require that a JW amount was not administered to any patient, and the record should be consistent with the units billed. Practices that also bill stricter Medicare Advantage or commercial contracts can add date, time, and reason fields without treating those fields as a fee-for-service CMS form. This documentation aligns with the package-to-claim reconciliation described in biosimilar invoice NDC HCPCS package unit reconciliation, where purchasing units and administered units must trace cleanly back to inventory records.

Claim-line mechanics: JW lines, JZ attestations, and the billing-unit trap

The operational submission of single-dose container claims requires precise claim-line structuring on professional (CMS-1500 / 837P) and institutional (CMS-1450 / UB-04) billing formats. When medication is discarded, the claim must contain two separate, complete claim lines for the same HCPCS code. Line 1 reports the HCPCS code without any modifier, indicating the exact number of billing units administered to the patient, accompanied by the standard charge for that portion. Line 2 reports the identical HCPCS code appended with modifier JW, indicating the exact number of billing units discarded, along with the corresponding line charge. When no medication is discarded, the claim consists of a single claim line reporting the total administered billing units appended with modifier JZ.

The most frequent and costly compliance error in Part B drug billing is the billing-unit trap. Healthcare providers frequently assume that whenever liquid remains in a single-dose vial, a JW modifier line is automatically warranted. CMS Claims Processing Manual Chapter 17 Section 40 explicitly refutes this assumption: "When the billing unit equals or exceeds the actual dose plus the discarded amount, JW is not permitted."

Consider an injectable assigned a HCPCS descriptor of "per 10 mg." A physician administers 7 mg from a 10 mg single-dose vial and discards the remaining 3 mg. CMS does not accept a fractional billing unit, so the 7 mg dose is billed as one unit. That unit already covers the 10 mg vial. If the claim also adds a JW line of one unit, it reports two units, or 20 mg. The manual example for this pattern is a single line of one unit with modifier JZ.

A second critical mechanical constraint involves Medically Unlikely Edits (MUEs). CMS develops MUEs to define the maximum units of service that a provider would report under most circumstances for a single beneficiary on a single date of service. For Part B drug claims, MAC claims processing systems apply the MUE limit to the cumulative sum of units reported across Line 1 (administered) and Line 2 (discarded). For instance, as noted in Noridian Part B guidance for infliximab (J1745), the daily MUE limit is 150 units. If an exceptionally high dose and discarded residual combine to exceed the published MUE value, the entire claim will be automatically rejected or suspended for manual review, irrespective of valid medical record documentation.

Setting map: office, OPPS, ASC, CAH, ESRD, suppliers, and the vaccine carve-out

The requirement to report modifiers JW and JZ is not universal across all Medicare settings; rather, it is strictly calibrated by place of service and statutory payment methodology. While physician offices billing on professional claims must report the modifiers on all separately payable single-dose drugs, institutional providers operating under prospective payment systems must evaluate specific status and payment indicators.

Under the Hospital Outpatient Prospective Payment System (OPPS), hospitals billing on CMS-1450 (UB-04) forms must report JW or JZ only for drugs assigned OPPS Status Indicator G (pass-through drugs and biologicals) or Status Indicator K (non-pass-through drugs and biologicals paid under OPPS APCs). Hospitals must never report JW or JZ for drugs assigned Status Indicator N. Drugs with Status Indicator N are packaged into primary procedural APCs; because packaged drugs do not generate separate fee-schedule payments, appending discard modifiers generates billing errors and distorts hospital cost-report data. Similarly, Ambulatory Surgical Centers (ASCs) must report JW and JZ only for separately payable drugs assigned Payment Indicator K2; packaged ASC drugs (Payment Indicator N1) are exempt.

Effective January 1, 2025, the CMS FAQ and Claims Processing Manual Revision 13108 require a billing supplier that prepares a single-dose drug but does not administer it to report JW when an amount is discarded during preparation, and JZ when no amount is discarded during preparation. The rule covers preparation before the drug is supplied to the patient. It does not create a new payment right for multi-dose containers or for overfill.

Additionally, providers billing unclassified or Not Otherwise Classified (NOC) drug codes (such as J3490, J3590, or J9999) on professional claims must report JW or JZ whenever the underlying product is furnished from a single-dose container. As examined in our companion report on J-code timing and interim billing risk for buy-and-bill biologics, interim NOC billing carries elevated audit scrutiny. In the hospital outpatient setting, NOC codes generally require modifiers, with the sole exception of code C9399 (unclassified drugs under OPPS), which CMS exempts from JW/JZ reporting.

Worked record example: a 100-unit vial and a 95-unit dose

The worked example below uses the CMS manual numbers only. It is not a patient case and it does not state a Medicare payment amount. A separately payable drug, shown here with hypothetical HCPCS code J9998 and a billing unit of 1 unit, is drawn as 95 units from a single-dose container labeled 100 units. The remaining 5 units are discarded and are not administered to any patient.

A record that matches those units can be written in whatever format the practice already uses. The fields below are the ones the claim has to be able to support. Names, dates of birth, diagnoses, NDCs, and lot numbers are left blank on purpose.

Based upon this unambiguous clinical record, the revenue cycle department generates the compliant two-line claim. Notice that both lines carry the identical HCPCS code, date of service, and NDC crosswalk, but Line 2 appends modifier JW to segregate the non-administered units:

Now contrast this with the multi-vial infliximab example documented in Noridian MAC billing guidance. When an adult rheumatoid arthritis patient receives a 350 mg infusion of infliximab (J1745, 10 mg per billing unit), the infusion suite accesses four 100 mg single-dose vials (totaling 400 mg). The nurse administers 350 mg (35 billing units) and discards the remaining 50 mg (5 billing units) from the fourth vial. The compliant claim reports J1745 with 35 units on Line 1 (no modifier) and J1745 with modifier JW and 5 units on Line 2. Both lines together account for 40 units (400 mg), matching the physical purchase of four 100 mg vials.

Reconciling these billing mechanics is vital for preserving practice margin, especially in competitive specialty therapeutic classes. As detailed in our analysis of biosimilar HCPCS NDC crosswalk errors and claims denial, crosswalk mismatches between the administered NDC and the billed HCPCS code are magnified when modifier JW is appended, triggering manual review and delayed payment.

Why the record now prices a manufacturer refund

Until 2023, modifier JW was mainly a claims flag for discarded amounts from a single-dose container. Section 90004 of the Infrastructure Investment and Jobs Act then added Section 1847A(h) of the Social Security Act. For refundable single-dose container or single-use package drugs payable under Part B, manufacturers pay CMS a quarterly refund on certain discarded amounts. CMS identifies those discarded billing units from provider claims that report modifier JW.

The statutory refund calculation, codified at 42 CFR § 414.940, operates on a quarterly schedule. CMS determines the refund amount by multiplying the aggregate discarded billing units reported under modifier JW by the applicable Part B payment amount (typically ASP + 6%), and then subtracting an applicable percentage of estimated total allowed charges for that drug in that quarter. In essence, the statute establishes a permitted wastage tolerance; manufacturers owe refunds only on discarded drug amounts that exceed the statutory threshold.

Under 42 CFR § 414.940, CMS established specific applicable percentage tiers to accommodate distinct pharmacological and clinical delivery profiles:

The financial magnitude of this program is immense. In the CY 2027 Physician Fee Schedule Proposed Rule (91 FR 43842, July 16, 2026), CMS officially reported that in December 2025, it issued annual refund assessment reports to biopharmaceutical manufacturers covering updated CY 2023 quarters and new CY 2024 quarters. Aggregate refund liabilities assessed against manufacturers for those quarters exceeded $173 million. The proposed rule states that the refunds owed for those quarters amount to more than $173 million and that the amount was deposited into the Supplementary Medical Insurance Trust Fund, as the statute requires. A manufacturer that disputes the report submits an error report within 30 days after the report is issued. If a manufacturer fails to pay the refund required under 42 CFR § 414.940, the Secretary imposes a civil money penalty under § 414.940(g) equal to the unpaid refund plus 25 percent of that refund.

The CY 2026 Physician Fee Schedule final-rule fact sheet says CMS reviewed two applications for a higher applicable percentage and finalized no change for either drug. The CY 2027 proposed rule (91 FR 43842, July 16, 2026) discusses one application, from the manufacturer of Leukine (sargramostim), asking again for a 72 percent applicable percentage. The 72 percent figure in the application is tied to a much smaller potential adjuvant dose, not to a finding that current labeled use already discards 72 percent. CMS proposed not to increase the percentage, writing that existing discarded-amount claims data do not support the unique-circumstances finding the statute requires. Comments closed on September 14, 2026. The final decision is still pending.

For market access and brand teams, this program bridges clinical revenue cycle management directly to gross-to-net accounting. If provider infusion suites erroneously bill modifier JW when JZ was warranted—such as in the billing-unit trap scenario—or if clinics document excess waste due to incorrect vial size selection, those provider errors directly inflate the manufacturer’s corporate refund liability. Managing provider education and packaging optimization is now an essential commercial priority, closely tied to the ASP dynamics analyzed in our review of revised CMS ASP file version date code reconciliation and ASP lag in launch buy-and-bill economics during first quarters.

Before you bill: the pre-submission checklist and what to re-verify

Before submission, check the container, the billing unit, the claim lines, the record, and the setting. The list below is an operating check, not a guarantee of payment or of audit clearance:

1. Container Verification: Confirm via the FDA package insert that the drug is labeled as a Single-Dose Container or Single-Use Package. If labeled as a Multi-Dose Container, bill administered units only without JW or JZ.

2. Billing Unit Test: Verify whether one whole HCPCS billing unit equals or exceeds the total dose administered plus discarded. If one unit covers the entire vial, bill a single line of 1 unit with modifier JZ. Never append JW if it results in overpayment.

3. Claim Line Architecture: Ensure that waste claims contain exactly two complete lines (administered with no modifier, discarded with JW). Ensure no-waste claims contain exactly one line with JZ.

4. Medical Record Triad: Confirm that the clinical chart records the actual dose administered, exact amount discarded, and total labeled container content, alongside a signed clinician wastage attestation.

5. Place of Service & Indicator Screening: If billing institutional claims under OPPS, verify that the drug carries Status Indicator G or K (never N). If ASC, verify Payment Indicator K2 (never N1).

6. MUE & Crosswalk Validation: Check that the combined units of Line 1 and Line 2 do not exceed the published daily MUE limit. Verify that the NDC package size matches the billed HCPCS billing unit.

Reimbursement specialists must also monitor regulatory re-verification triggers that periodically alter billing parameters:

• Semi-annual CMS HCPCS Code List updates: Monitor the CMS Part B Discarded Drugs page for newly added single-dose HCPCS codes.

• Annual OPPS and ASC payment indicator shifts: Every January 1, CMS reclassifies dozens of drug status indicators between G, K, and packaged status N.

• Annual PFS rulemaking updates: Track annual Physician Fee Schedule final rules (expected each November) for modifications to refundable drug definitions, orphan drug thresholds, and applicable percentage determinations.

• Local MAC article churn: Local coverage guidance evolves frequently. For instance, Noridian MCD Article A55932 was formally retired on September 25, 2025 and consolidated into a unified JE/JF billing and coding article. Providers must ensure their internal billing rules reflect live MAC instructions rather than retired coverage articles.

Re-check the CMS HCPCS list, the year’s OPPS and ASC indicators, the next PFS final rule on applicable percentages, and the current MAC article before treating any of those items as settled. Noridian article A55932 was retired on September 25, 2025, and merged into a unified JE/JF billing and coding article, which is a reminder that local instructions move.

Sources

• Centers for Medicare & Medicaid Services. Discarded Drugs (Medicare Part B) Payment Policy Overview. Current as of September 2026.

• Centers for Medicare & Medicaid Services. Medicare Program Discarded Drugs and Biologicals - JW Modifier and JZ Modifier Policy Frequently Asked Questions. Updated January 10, 2025.

• Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual, Pub. 100-04, Chapter 17, Section 40: Discarded Drugs and Biologicals. Revision 13108, effective January 1, 2025.

• Office of the Federal Register. 42 CFR § 414.940 - Refund for certain discarded single-dose container or single-use package drugs. Electronic Code of Federal Regulations, current as of September 24, 2026.

• Office of the Federal Register. 42 CFR § 414.902 - Definitions: Refundable single-dose container or single-use package drug; low volume dose; refund quarters. Electronic Code of Federal Regulations, current as of September 24, 2026.

• Centers for Medicare & Medicaid Services. Medicare Program Discarded Drugs and Biologicals - JW Modifier and JZ Modifier Policy HCPCS Codes. Updated June 20, 2025.

• Centers for Medicare & Medicaid Services. CY 2027 Payment Policies Under the Physician Fee Schedule and Other Changes (Proposed Rule), 91 FR 43842. Published July 16, 2026; comments closed September 14, 2026.

• Centers for Medicare & Medicaid Services. Calendar Year (CY) 2026 Medicare Physician Fee Schedule Final Rule Fact Sheet (CMS-1832-F). Published November 2025.

• Noridian Healthcare Solutions. Billing and Coding: JW and JZ Modifier Billing Guidelines (MCD Article A55932). Original effective January 1, 2018; retired September 25, 2025.

• Noridian Healthcare Solutions. Drug Wastage - JW and JZ Modifiers. Jurisdiction E Part B Guidance, accessed September 24, 2026.

• Blue Cross Blue Shield of Michigan. Billing Instructions: Using Modifiers JW and JZ (Commercial and Medicare Advantage). Published February 2026.

• Blue Cross and Blue Shield of Illinois. Clinical Payment and Coding Policy CPCP017: Wasted/Discarded Drugs and Biologicals. Current as of 2026.

• National Infusion Center Association. Managing JW and JZ Modifiers When Billing Single-Dose Drugs. Clinical Practice Guidance, accessed September 24, 2026.

• American Academy of Ophthalmology. Fact Sheet: JW and JZ Modifiers. American Academy of Ophthalmic Executives, published June 5, 2023.